Real-World Evidence on Prognostic Value of MRD in Multiple
Myeloma Using Flow Cytometry

J 2025

Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry

MURONOVA, Ludmila; Ondrej SOUCEK; David ZIHALA; Tereza SEVCIKOVA; Tereza POPKOVA et al.

Základní údaje

Originální název

Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry

Autoři

Vydání

European Journal of Haematology, Hoboken, Wiley-Blackwell, 2025, 0902-4441

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.300 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00140372

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

lenalidomide maintenance; minimal residual disease (MRD); multiparameter flow cytometry; multiple myeloma; overall survival (OS); progression-free survival (PFS); real-world

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 4. 4. 2025 13:08, Mgr. Tereza Miškechová

Anotace

V originále

Minimal residual disease (MRD) is one of the most important prognostic factors in multiple myeloma (MM) and a valid surrogate for progression-free survival (PFS) and overall survival (OS). Recently, MRD negativity was approved as an early clinical endpoint for accelerated drug approval in MM. Nevertheless, there is limited evidence of MRD utility in real-world setting. In this retrospective multicenter study, we report outcomes of 331 newly diagnosed MM patients with MRD evaluation at Day+100 after autologous stem cell transplantation using flow cytometry with a median limit of detection of 0.001%. MRD negativity was reached in 47% of patients and was associated with significantly prolonged median PFS (49.2 months vs. 18.4 months; hazard ratios (HR) = 0.37; p < 0.001) and OS (not reached vs. 74.9 months; HR = 0.50; p = 0.007). Achieving MRD negativity was associated with PFS improvements regardless of age, International Staging System (ISS) stage, lactate dedydrogenase (LDH) level, or cytogenetic risk. Importantly, MRD positive patients benefited from lenalidomide maintenance versus no maintenance (18-months PFS: 81% vs. 46%; HR = 0.24; p = 0.002) while in MRD negative patients such benefit was not observed (p = 0.747). The outcomes of our real-world study recapitulate results from clinical trials including meta-analyses and support the idea that MRD positive patients profit more from lenalidomide maintenance than MRD negative ones.

Návaznosti

90254, velká výzkumná infrastruktura

Název: e-INFRA CZ II

Citovat

MURONOVA, Ludmila; Ondrej SOUCEK; David ZIHALA; Tereza SEVCIKOVA; Tereza POPKOVA; Hana PLONKOVA; Ondrej VENGLAR; Luděk POUR; Martin ŠTORK; Lucie RIHOVA; Renata BEZDEKOVA; Jiri MINARIK; Vojtech LATAL; Martin NOVAK; Alexandra JUNGOVA; Tereza DEKOJOVA; Jan STRAUB; Martin SPACEK; Vladimira REZACOVA; Vladimir MAISNAR; Jakub RADOCHA; Roman HAJEK a Tomas JELINEK. Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry. European Journal of Haematology. Hoboken: Wiley-Blackwell, 2025, roč. 114, č. 1, s. 155-163. ISSN 0902-4441. Dostupné z: https://doi.org/10.1111/ejh.14316.

@article{2447837,
   author = {Muronova, Ludmila and Soucek, Ondrej and Zihala, David and Sevcikova, Tereza and Popkova, Tereza and Plonkova, Hana and Venglar, Ondrej and Pour, Luděk and Štork, Martin and Rihova, Lucie and Bezdekova, Renata and Minarik, Jiri and Latal, Vojtech and Novak, Martin and Jungova, Alexandra and Dekojova, Tereza and Straub, Jan and Spacek, Martin and Rezacova, Vladimira and Maisnar, Vladimir and Radocha, Jakub and Hajek, Roman and Jelinek, Tomas},
   article_location = {Hoboken},
   article_number = {1},
   doi = {https://doi.org/10.1111/ejh.14316},
   keywords = {lenalidomide maintenance; minimal residual disease (MRD); multiparameter flow cytometry; multiple myeloma; overall survival (OS); progression-free survival (PFS); real-world},
   language = {eng},
   issn = {0902-4441},
   journal = {European Journal of Haematology},
   title = {Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/ejh.14316},
   volume = {114},
   year = {2025}
}

TY  - JOUR
ID  - 2447837
AU  - Muronova, Ludmila - Soucek, Ondrej - Zihala, David - Sevcikova, Tereza - Popkova, Tereza - Plonkova, Hana - Venglar, Ondrej - Pour, Luděk - Štork, Martin - Rihova, Lucie - Bezdekova, Renata - Minarik, Jiri - Latal, Vojtech - Novak, Martin - Jungova, Alexandra - Dekojova, Tereza - Straub, Jan - Spacek, Martin - Rezacova, Vladimira - Maisnar, Vladimir - Radocha, Jakub - Hajek, Roman - Jelinek, Tomas
PY  - 2025
TI  - Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry
JF  - European Journal of Haematology
VL  - 114
IS  - 1
SP  - 155-163
EP  - 155-163
PB  - Wiley-Blackwell
SN  - 09024441
KW  - lenalidomide maintenance
KW  - minimal residual disease (MRD)
KW  - multiparameter flow cytometry
KW  - multiple myeloma
KW  - overall survival (OS)
KW  - progression-free survival (PFS)
KW  - real-world
UR  - https://onlinelibrary.wiley.com/doi/10.1111/ejh.14316
N2  - Minimal residual disease (MRD) is one of the most important prognostic factors in multiple myeloma (MM) and a valid surrogate for progression-free survival (PFS) and overall survival (OS). Recently, MRD negativity was approved as an early clinical endpoint for accelerated drug approval in MM. Nevertheless, there is limited evidence of MRD utility in real-world setting. In this retrospective multicenter study, we report outcomes of 331 newly diagnosed MM patients with MRD evaluation at Day+100 after autologous stem cell transplantation using flow cytometry with a median limit of detection of 0.001%. MRD negativity was reached in 47% of patients and was associated with significantly prolonged median PFS (49.2 months vs. 18.4 months; hazard ratios (HR) = 0.37; p < 0.001) and OS (not reached vs. 74.9 months; HR = 0.50; p = 0.007). Achieving MRD negativity was associated with PFS improvements regardless of age, International Staging System (ISS) stage, lactate dedydrogenase (LDH) level, or cytogenetic risk. Importantly, MRD positive patients benefited from lenalidomide maintenance versus no maintenance (18-months PFS: 81% vs. 46%; HR = 0.24; p = 0.002) while in MRD negative patients such benefit was not observed (p = 0.747). The outcomes of our real-world study recapitulate results from clinical trials including meta-analyses and support the idea that MRD positive patients profit more from lenalidomide maintenance than MRD negative ones.
ER  -

MURONOVA, Ludmila; Ondrej SOUCEK; David ZIHALA; Tereza SEVCIKOVA; Tereza POPKOVA; Hana PLONKOVA; Ondrej VENGLAR; Luděk POUR; Martin ŠTORK; Lucie RIHOVA; Renata BEZDEKOVA; Jiri MINARIK; Vojtech LATAL; Martin NOVAK; Alexandra JUNGOVA; Tereza DEKOJOVA; Jan STRAUB; Martin SPACEK; Vladimira REZACOVA; Vladimir MAISNAR; Jakub RADOCHA; Roman HAJEK a Tomas JELINEK. Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry. \textit{European Journal of Haematology}. Hoboken: Wiley-Blackwell, 2025, roč.~114, č.~1, s.~155-163. ISSN~0902-4441. Dostupné z: https://doi.org/10.1111/ejh.14316.

Přehled o publikaci